Doximity Reports Q3 FY26 Results, Authorizes $500M Stock Repurchase, and Announces CFO Medical Leave
DOCS is trading near its 52-week low of $32.66 (8.0% below the low) on elevated volume (2.6× avg).
Summary
Doximity announced Q3 FY26 results with mixed financial metrics, a significant $500 million stock repurchase program, and a temporary medical leave for its CFO with an internal interim replacement.
Key Events · Earnings and Guidance · DOCS
-
Q3 FY26 Financial Results Announced
Doximity reported Q3 FY26 revenue of $185.1 million (up 10% Y/Y), net income of $61.6 million (down from $75.2M Y/Y), and Adjusted EBITDA of $111.4 million (up 9% Y/Y). Diluted EPS was $0.31 (down from $0.37 Y/Y), while non-GAAP diluted EPS was $0.46 (up from $0.45 Y/Y).
-
New $500 Million Stock Repurchase Program Authorized
The Board of Directors authorized a new program to repurchase up to $500 million of Class A common stock. This substantial capital return initiative comes as the stock trades below its 52-week low, indicating management's confidence in the company's valuation.
-
CFO Takes Temporary Medical Leave
Anna Bryson, the company's Chief Financial Officer, is taking a temporary medical leave of absence. Siddharth Sitaram, Chief Accounting Officer, has been appointed interim principal financial and accounting officer, leveraging his internal experience.
-
Updated Fiscal Year 2026 Guidance
The company updated its fiscal year 2026 guidance, projecting revenue between $642.5 million and $643.5 million, and Adjusted EBITDA between $355.5 million and $356.5 million.
Analysis · DOCS · Technology
Doximity's latest 8-K filing presents a mixed financial picture alongside a significant capital allocation decision and a temporary executive change. While GAAP net income and diluted EPS saw year-over-year declines, the company reported a 10% increase in revenue and a 9% rise in Adjusted EBITDA, with non-GAAP diluted EPS slightly increasing. The most impactful announcement is the authorization of a new $500 million stock repurchase program, which represents a substantial portion of the company's market capitalization. This move is particularly noteworthy as the stock is currently trading below its 52-week low, signaling strong management confidence in the company's valuation and a commitment to shareholder returns. Additionally, the CFO is taking a temporary medical leave, with an experienced internal Chief Accounting Officer stepping in as interim, which helps mitigate potential disruption.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1075 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DOCS was trading at $30.05 on NYSE in the Technology sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $32.66 to $85.21. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.